Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Borayflo is an absorbable hemostatic fluid gelatin developed by Jiangxi Boen Ruier Biotechnology for intraoperative auxiliary hemostasis. It is designed to control bleeding during surgical procedures when conventional methods, such as pressure or ligatures, are ineffective or impractical. The product consists of a gelatin matrix that, when applied to a bleeding site, provides a physical scaffold that promotes platelet aggregation and facilitates the formation of a stable fibrin clot. As a flowable hemostat, it is particularly useful for reaching irregular or difficult-to-access surgical areas. It is intended to be fully absorbed by the body within several weeks of application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Borayflo.